Core Viewpoint - Johnson Fistel, PLLP is investigating claims against SentinelOne, Inc. regarding alleged misconduct by its officers and directors, which may impact shareholders who have held shares since June 1, 2022 [1][2]. Group 1: Investigation Details - The investigation focuses on claims that SentinelOne's officers and directors made false or misleading statements and failed to disclose significant issues, including ineffective internal controls over accounting and financial reporting [2]. - Allegations include that SentinelOne's Annualized Recurring Revenue (ARR) was overstated, leading to inflated guidance from the company [2]. Group 2: Legal Context - A class action complaint has already been filed against SentinelOne, indicating ongoing legal challenges for the company [2]. - Shareholders may have the opportunity to hold the company's officers and directors personally responsible for the alleged harm [2]. Group 3: Law Firm Background - Johnson Fistel, PLLP is a nationally recognized law firm specializing in shareholder rights and securities class action lawsuits, with multiple offices across the United States [3]. - The firm has a strong track record, having recovered approximately $90,725,000 for clients in cases where it served as lead or co-lead counsel [4].

SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Red Cat Holdings, Inc. (NASDAQ: RCAT) securities between March 18, 2022 and January 15, 2025. Red Cat, together with its subsidiaries, provides various products, services, and solutions to the U.S. drone industry. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins ...

Core Viewpoint - Johnson Fistel, PLLP is investigating potential breaches of fiduciary duties by directors and officers of Quantum Computing Inc. (QCI), focusing on their obligations to shareholders [1]. Group 1: Legal Investigation - A class action complaint has been filed against QCI, alleging that the defendants made false and misleading statements regarding the company's quantum computing technologies and relationships with NASA [3]. - The complaint claims that QCI overstated its technological capabilities, the nature of its contracts with NASA, and its progress in developing a TFLN foundry [3]. - It is alleged that QCI's revenues were partially based on undisclosed related party transactions, which could significantly harm the company's business and reputation once revealed [3]. Group 2: Shareholder Rights - Current long-term QCI shareholders may have legal claims that can be brought against the company's directors and officers [2]. - Shareholders interested in discussing their legal rights are encouraged to contact the lead analyst at Johnson Fistel [2].

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) securities between May 9, 2024, and May 8, 2025, alleging that the company misled investors regarding its business prospects [1][2]. Group 1: Allegations Against Iovance Biotherapeutics - The complaint states that Iovance failed to disclose that new Authorized Treatment Centers (ATCs) were facing longer timelines to begin treating patients with Amtagvi [2]. - It is alleged that the company's sales team and new ATCs were ineffective in identifying and selecting patients for Amtagvi, resulting in higher patient drop-offs [2]. - These issues led to increased costs and decreased revenue, as ATCs could not keep up with the manufactured product, making the company's positive statements about its business misleading [2]. Group 2: Financial Performance - On May 8, 2025, Iovance reported a quarterly total product revenue of $49.3 million, down from $73.7 million in the previous quarter [3]. - The company revised its full fiscal year 2025 total product revenue guidance from $450 million - $475 million to $250 million - $300 million, representing a reduction of over 40% at the midpoint [3]. - The updated forecast was attributed to recent launch dynamics of Amtagvi and the growth trajectories and treatment timelines for new ATCs [3]. Group 3: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers with the court by July 14, 2025 [4]. - Participation in the case is not required to be eligible for recovery, allowing shareholders to remain absent class members if they choose [4].

SAN DIEGO, June 02, 2025 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP has launched an investigation into whether the board members of Blueprint Medicines Corporation (NASDAQ: BPMC) breached their fiduciary duties in connection with the proposed sale of the Company to Sanofi (NASDAQ: SNY). On June 2, 2025, Blueprint Medicines announced the execution of a definitive agreement with Sanofi for the acquisition of all outstanding shares of Blueprint Medicines for $129.00 per share in cash. Whereas shareholders also ...

Core Viewpoint - Robbins LLP has initiated a class action lawsuit on behalf of investors who purchased NET Power Inc. securities between June 9, 2023, and March 7, 2025, alleging that the company misled investors regarding the timeline and costs associated with Project Permian [1][2]. Group 1: Allegations and Financial Impact - The lawsuit claims that NET Power failed to disclose that Project Permian was unlikely to be completed on schedule and would incur significantly higher costs due to supply chain issues and site-specific challenges [2]. - Following the announcement of third quarter 2023 results, NET Power's stock fell over 18% after revealing a 12-month delay in the project timeline, now expecting initial power generation between the second half of 2027 and first half of 2028 [3]. - On March 10, 2025, NET Power disclosed that the total installed cost for Project Permian is now estimated to be between $1.7 billion and $2.0 billion, a significant increase from the previous estimate of $1.1 billion, and announced a further delay to no earlier than 2029, causing the stock price to drop over 31% [4]. Group 2: Class Action Participation - Shareholders interested in serving as lead plaintiffs in the class action must file their papers by June 17, 2025, although participation is not required to be eligible for recovery [5].

SAN DIEGO, May 27, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Red Cat Holdings, Inc. (NASDAQ: RCAT) securities between March 18, 2022 and January 15, 2025. Red Cat, together with its subsidiaries, provides various products, services, and solutions to the U.S. drone industry. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003. The Allegations: Robbins ...

Core Viewpoint - Robbins LLP is investigating Proficient Auto Logistics, Inc. for potential violations of securities laws and breaches of fiduciary duties by its officers and directors [1]. Group 1: Company Overview - Proficient Auto Logistics, Inc. operates in the auto transportation and logistics services sector in North America [1]. Group 2: Legal Investigation - The investigation by Robbins LLP aims to determine if there have been any breaches of fiduciary duties to shareholders by the company's executives [1]. - Shareholders who have incurred losses in their investments are encouraged to contact Robbins LLP for more information regarding their rights [2]. Group 3: Robbins LLP Background - Robbins LLP has been active in shareholder rights litigation since 2002, focusing on helping shareholders recover losses and improve corporate governance [3]. - The firm has successfully obtained over $1 billion for shareholders since its inception [3].

PALO ALTO, Calif., May 22, 2025 /PRNewswire/ -- Glenbrook Capital Management ("Glenbrook" or "we"), a long-time shareholder of Tejon Ranch Co. (NYSE:TRC) ("Tejon" or the "Company") and owner of approximately 1.1% of outstanding shares of Tejon, today urged Tejon's Board of Directors (the "Board") to implement PFS Trust's shareholder proposal to allow Tejon shareholders owning a combined 10% of outstanding shares to call a special meeting of shareholders (the "Special Meeting Proposal"). Glenbrook also quest ...

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against BioAge Labs, Inc. due to a class action complaint related to the company's IPO and alleged breaches of fiduciary duties by its board of directors [1] Group 1: Legal Investigation - A class action complaint was filed against BioAge on January 7, 2024, concerning its registration statement for the IPO held on September 26, 2024 [1] - The investigation focuses on whether BioAge's board of directors has breached their fiduciary duties to the company [1] Group 2: Product and Market Impact - On December 6, 2024, BioAge announced the discontinuation of the STRIDES Phase 2 trial for its lead product candidate, azelaprag, due to safety concerns related to elevated liver transaminase levels [2] - This announcement was unexpected, as BioAge had previously highlighted azelaprag's potential in patients undergoing obesity therapy with incretin drugs during its IPO [2] Group 3: Stock Price Reaction - Following the announcement regarding the discontinuation of the trial, BioAge's stock price fell significantly from $20.09 per share on December 6, 2024, to $4.65 per share on December 7, 2024 [3]